Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Nuwellis, Inc. NUWE

Healthcare — Medical Devices

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
3.51
Revenue
9.01
Net Income
(11.32)
Free Cash Flow
(12.68)
Net Debt
(3.92)
Current Ratio
1.97
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.02
P/B ratio
0.00
Past 5Y EPS Growth
90.39%
This Y EPS Growth
92.50%
Next Y EPS Growth
72.49%
Next 5Y EPS Growth
85.85%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 3.80 5.10 1.09 3.92
Receivables 1.95 1.73 1.49 1.55
Inventory 2.00 1.72 1.91 1.74
Other 0.46 0.32 0.70 0.69
8.21 8.86 5.19 7.90
2023 2024 2025 Q'26
Payables 2.38 1.64 2.23 2.90
ST’ Debt — — — —
Other 0.05 0.04 0.09 0.18
3.17 2.56 3.03 4.01
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 2.40 1.97 — —
—
’25 1.90 1.73 2.22 2.42
8.27
’24 1.86 2.19 2.37 2.32
8.74
’23 1.83 2.08 2.41 2.55
8.86
’22 1.93 2.21 2.07 2.34
8.54
’21 1.92 2.51 1.85 1.64
7.92
’20 1.63 1.86 1.90 2.04
7.44
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (3.11) (3.17) — —
—
’25 (2.54) (2.10) (3.15) (3.03)
(10.81)
’24 (2.86) (2.75) (2.47) (1.50)
(9.59)
’23 (6.11) (5.25) (3.82) (2.75)
(17.94)
’22 (4.83) (3.94) (3.26) (3.13)
(15.15)
’21 (5.38) (3.82) (4.49) (4.15)
(17.84)
’20 (5.49) (3.26) (4.40) (3.41)
(16.57)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.23) (3.18) — —
—
’25 (2.54) (2.10) (3.24) (3.02)
(10.90)
’24 (2.89) (2.78) (2.45) (1.53)
(9.65)
’23 (6.20) (5.32) (3.95) (2.72)
(18.18)
’22 (4.90) (3.95) (3.28) (3.15)
(15.27)
’21 (5.44) (3.90) (4.54) (4.18)
(18.06)
’20 (5.51) (3.32) (4.54) (3.47)
(16.84)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (73.08) (26.64) — —
—
’25 (1.01k) (2.13k) 19.58 (52.45)
(887.76)
’24 (30.82k) (27.69k) 2.56k (646.41)
(12.36k)
’23 (295.88k) (187.49k) (92.98k) (115.06k)
(591.76k)
’22 (2.16m) (2.11m) (1.90m) (256.84k)
(4.29m)
’21 (6.42m) (3.70m) (3.85m) (2.11m)
(14.74m)
’20 (57.08m) (15.43m) (10.68m) (5.80m)
(54.81m)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 312,816.00 21,094.50 1,352.40 59.85 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,518,250.00 615,342.00 44,247.00 2,454.90 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 70 59 19 24 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.12 0.15 0.46 0.34 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.54 8.86 8.74 8.27 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55.66% 56.22% 64.94% 61.96% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.52) (20.20) (11.16) (17.52) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (169.92%) (227.90%) (127.69%) (211.80%) ‡‡‡ ‡‡‡ —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.52) (20.21) (11.16) (17.52) ‡‡‡‡‡ ‡‡‡‡‡ —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.37 0.36 0.31 0.20 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 9,711.11 419.80 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4,291,780.00) (591,757.10) (12,355.29) (887.76) ‡‡‡‡‡ ‡‡‡‡‡ —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 (10,656.67) (548.73) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 (66.67) (4.57) ‡‡‡ ‡‡‡ —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 (10,723.33) (553.30) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 7,255.56 133.50 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.02 ‡‡‡‡‡ ‡‡‡‡‡ —
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 0.17 0.15 ‡‡‡ ‡‡‡ —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 0.23 0.46 ‡‡‡ ‡‡‡ —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.03) (0.34) (0.32) 0.11 ‡‡‡‡ ‡‡‡‡ —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.13 0.16 0.29 (0.09) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.15) (17.94) (9.59) (10.81) ‡‡‡ ‡‡‡ —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.12) (0.25) (0.06) (0.09) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.27) (18.18) (9.65) (10.90) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.08 5.04 6.30 2.15 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.98 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.32) (3.80) (5.09) (1.08) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.36 3.21 6.53 2.63 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (52.73%) (131.39%) (108.22%) (219.21%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00% 0.00% (478.57%) (449.27%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (75.84%) (294.87%) (223.24%) (382.80%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Nuwellis, Inc. (NUWE), a microcap medtech player in renal therapies for fluid overload, has shown gritty operational resilience—FDA wins for its Aquadex system, gross margins soaring to 65% in 2024, and leaner ops with employee cuts boosting revenue per head to $460K—despite a brutal decade of dilutions, reverse splits, and a Nasdaq scare. Revenue stabilized at $8-9M after early 30% CAGR surges, with forecasts eyeing a V-shaped rebound to $10.7M by 2027, while losses narrow 29% cumulatively and cash burn improves, backed by a debt-free $5M net cash position.

Yet, this cash-rich deep value (PS 0.17x, PB 0.23x) trades at rock-bottom multiples, with unanimous analyst targets screaming 23,400% upside—a statistical moonshot z-score >5 that insiders ignore amid zero activity and equity erosion. Contrarian flags wave high: dilution precedents, 75% odds of revenue misses, and Baxter-scale competition could torch the bull case, but margin momentum and trial tailwinds skew expected returns massively positive if execution clicks—watch Q1 2026 for the inflection tell.

Read full commentary →

Nuwellis, Inc. (NUWE) Latest News

News by impact score

Fine-tune

17 Sep

3 investorshub.advfn.com, 10:23 AM
Nuwellis sold 31 Aquadex consoles in 2026, expanding recurring revenue opportunity. Console sales growth directly supports recurring revenue expansion for Nuwellis core product line.

3 , 8:30 AM
Nuwellis sold 31 Aquadex SmartFlow consoles year-to-date, indicating strong adoption and expanding recurring revenue opportunities. Console sales growth supports higher recurring revenue from the Aquadex system.

9 Sep

3 , 8:30 AM
Nuwellis advances financial efficiency strategy via improved gross margins. Improved gross margins indicate better operational efficiency likely to lift profitability and investor views.

25 Aug

3 , 8:30 AM
Nuwellis enters strategic commercial agreement with Atrility Medical to expand its critical care portfolio. Agreement adds portfolio expansion but lacks details on revenue scale or market shift.

13 Aug

3 , 7:05 PM
Nuwellis Inc reported 14% revenue growth in Q2 2026 along with expansion of its installed base during the earnings call. Revenue surge and installed base growth point to stronger commercial traction that can lift near-term financial results.

3 , 8:00 AM
Nuwellis reports Q2 2026 results with double digit revenue growth and expanded gross margin. Double digit revenue growth and margin expansion in quarterly results signal moderate improvement in financial performance.

11 Aug

3 , 3:30 AM
Nuwellis advances Aquadex platform digital transformation with EHR connectivity and enhanced user interface. Aquadex EHR connectivity and UI upgrades may improve usability and integration for moderate operational gains.

4 Aug

4 , 8:30 AM
Nuwellis announces strategy for next-generation Aquadex platform to expand future critical care applications. Next-generation Aquadex platform strategy targets expanded critical care markets and product positioning.

31 Jul

3 , 8:39 AM
Nuwellis, Inc. prices $3.4 million registered direct offering at-the-market under Nasdaq rules. Registered direct offering supplies operational capital but triggers share dilution with moderate effect on near-term performance.

27 Jul

3 , 8:30 AM
Nuwellis reports preliminary second quarter 2026 revenue results with double-digit growth. Double-digit revenue growth signals improved financial performance likely to moderately influence market sentiment and near-term valuation.

3 www.medicaldevice-network.com, 8:11 AM
Nuwellis installs new CEO to establish robust foundation for sustainable value creation. New CEO appointment introduces potential strategic adjustments without immediate major operational shifts.

16 Jul

4 , 8:30 AM
Nuwellis, Inc. has been awarded a U.S. patent for novel catheter technology designed to enhance extracorporeal therapies. Patent grant directly strengthens Nuwellis core IP position in catheter-based extracorporeal therapies.

24 Jun

3 GlobeNewswire, 8:30 AM
Nuwellis incoming CEO Mike McCormick issued a letter to shareholders highlighting strategic priorities centered on pediatric market expansion and revenue generation. New CEO priorities on pediatric expansion and revenue signal moderate strategic influence on operations and market position.

16 Jun

3 , 8:30 AM
Nuwellis, Inc. appoints Mike McCormick as Chief Executive Officer. New CEO appointment at Nuwellis may moderately affect strategic direction and operations.

8 Jun

3 GlobeNewswire, 9:46 PM
Nuwellis closed its $6.0 million registered public offering. The offering supplies operating capital but dilutes existing shareholders without altering core business trajectory.

5 Jun

3 investorshub.advfn.com, 10:29 AM
Nuwellis priced a $6 million equity and warrant offering, triggering an immediate drop in its shares. Equity offering dilutes shareholders and raises fresh capital, producing short-term negative pressure on valuation without altering long-term operations.

3 GlobeNewswire, 8:30 AM
Nuwellis, Inc. priced a $6 million public offering. Public offering supplies operating capital but dilutes shareholders and pressures near-term stock performance.

14 May

4 GlobeNewswire, 8:30 AM
Nuwellis announces successful completion of FDA pre-submission 510(k) meeting to expand Aquadex label, confirming alignment on non-clinical testing, bench testing, and clinical data requirements for ultrafiltration in pediatric patients. Successful FDA pre-submission advances Aquadex label expansion into pediatrics, enabling potential new revenue streams and market growth.

12 May

4 GuruFocus.com, 7:01 PM
Nuwellis Inc (NUWE) reported strong revenue growth and strategic advancements in its Q1 2026 earnings call highlights. Strong revenue growth and strategic initiatives signal significant positive shifts in financial performance and market positioning.

4 app.moby.co, 1:19 PM
Nuwellis, Inc. (NUWE) released Q1 2026 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q1 earnings call summary discloses financial metrics, revenue updates, and strategic plans that can substantially sway investor sentiment and stock trajectory.

4 transcript www.fool.com, 10:07 AM
Nuwellis (NUWE) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, revenue updates, and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.

3 GlobeNewswire, 8:00 AM
Nuwellis, Inc. announced first quarter 2026 financial results. Quarterly financial results disclosure affects key financial performance metrics and market sentiment.

28 Apr

4 GlobeNewswire, 8:30 AM
Nuwellis, Inc. (NUWE) announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative dual lumen midline catheter technology. Patent allowance bolsters Nuwellis's IP portfolio and competitive positioning in medical device innovation.

16 Apr

3 GlobeNewswire, 8:30 AM
Nuwellis, Inc. (NUWE) welcomes back three former team members to accelerate commercial and clinical momentum. Rehiring experienced former team members bolsters internal capabilities for commercial and clinical advancement.

31 Mar

4 GlobeNewswire, 8:30 AM
Nuwellis Inc.'s pediatric category achieved approximately 50% of total U.S. revenue in 2025, marking a significant growth milestone. Pediatric category reaching 50% of U.S. revenue indicates major growth in a key segment, poised to significantly enhance financial performance and market positioning.

17 Mar

4 GlobeNewswire, 8:00 AM
Nuwellis, Inc. (NUWE) completes acquisition of Rendiatech, bolstering its renal and pulmonary care technology portfolio through integration of innovative fluid management solutions. Acquisition completion delivers major strategic expansion in core fluid management technologies, potentially boosting revenue and competitive positioning.

10 Mar

4 app.moby.co, 12:43 PM
Nuwellis, Inc. issued Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance for the medical device company focused on fluid management therapies. Q4 earnings call summary discloses year-end financials, revenue updates, and strategic outlook capable of significantly swaying investor sentiment and stock performance.

4 transcript www.fool.com, 10:00 AM
Nuwellis (NUWE) released the transcript of its Q4 2025 earnings call. Q4 earnings call transcript covers financial results, operational updates, and forward guidance that can significantly impact NUWE's stock trajectory and investor sentiment.

4 GlobeNewswire, 8:15 AM
Nuwellis, Inc. (NUWE) announced fourth quarter and full year 2025 financial results. Financial results announcements directly impact stock price, investor sentiment, and future valuation through revenue, earnings, and guidance details.

5 Mar

3 GlobeNewswire, 8:00 AM
Nuwellis, Inc. (NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy to advance its pediatric and cardiorenal strategies. Appointing a clinical strategy expert bolsters pediatric and cardiorenal initiatives, moderately impacting innovation and market positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us